Overview

An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The objective is to evaluate the efficacy and safety of two doses of SSR149415 (250 mg and 100 mg twice daily) compared to placebo and escitalopram 10 mg once daily in outpatients with major depressive disorder.
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi